BIG
ALT icon

Brooklyn Investment Group’s Altimmune ALT Stock Holding History

Brooklyn Investment Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-572
Closed -$2.21K – 748
2025
Q2 		$2.21K Buy
+572
New +$3.1K ﹤0.01% 2740

Other funds holding ALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brooklyn Investment Group's ALT Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Altimmune (ALT) in Q3 2025, closing a stake of 572 shares — an estimated $2.21K sold.

Brooklyn Investment Group first reported a position in ALT in Q2 2025 and held it in 1 quarter. The position peaked at $2.21K in Q2 2025. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 572 Altimmune shares in Q3 2025, an estimated $2.21K.
  • Brooklyn Investment Group first reported a position in Altimmune in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Altimmune position peaked at $2.21K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.